

IN THE CLAIMS

Please amend claims 60, 65, and 71-79, as shown below.

Please add new claims 80-87 as shown below.

60. (Currently Amended) An pharmaceutical formulation ~~in oral unit dosage form~~, comprising Glutathione, in combination with an effective amount of one or more of a pharmaceutically acceptable physiologic nitric oxide precursor, an antiviral composition, and an antimicrobial composition ~~said formulation being in such form adapted to modify vascular tone in an organism administered said formulation.~~

61. (Previously Amended) The formulation according to claim 60, wherein the formulation acts as a vasodilator through alteration of nitric oxide metabolism.

62. (Previously Amended) The formulation method according to claim 60, wherein the formulation is effective for treating pathological vasospasm.

63. (Previously Amended) The method according to claim 60, wherein the formulation is effective for treating sexual dysfunction.

64. (Previously Amended) The formulation according to claim 60, in combination with a drug effective to treat congestive heart failure.

65. (Currently Amended) The formulation according to claim 60, ~~further comprising~~ wherein said formulation is in unit dosage form and comprises a physiologic nitric oxide precursor.

66. (Previously Amended) The formulation according to claim 65, wherein the nitric oxide precursor is arginine.

67. (Previously Amended) The formulation according to claim 65, wherein said formulation comprises about 500 mg reduced L-glutathione, about 200 mg ascorbic acid, and about 200 mg arginine.

68. (Previously Amended) The formulation according to claim ~~60~~ 65, wherein the ~~nitric oxide precursor comprises a pharmaceutically acceptable vasodilator~~ formulation comprises a nitric oxide precursor and an antiviral composition.

69. (Previously Amended) The formulation according to claim ~~60~~ 65, wherein the nitric oxide precursor comprises an NO₂ functionality.

70. (Previously Amended) The formulation according to claim 69, wherein the nitric oxide precursor comprises an organic nitrate.

71. (Currently Amended) The formulation according to claim 60, wherein said formulation comprises a pharmaceutically acceptable antimicrobial ~~further comprising an~~ antibiotic agent.

72. (Currently Amended) ~~A pharmaceutical composition in oral unit dosage form, comprising in combination glutathione and~~ The formulation according to claim 60, comprising at least one of an antiviral or antimicrobial antibiotic agent.

73. (Currently Amended) The ~~pharmaceutical composition~~ formulation according to claim 72, wherein said antibiotic agent comprises an antibiotic having activity against mycoplasma infection.

74. (Currently Amended) The ~~pharmaceutical composition~~ formulation according to claim 72, wherein said antibiotic agent comprises ~~an antibiotic~~ a pharmaceutically acceptable antiviral composition having activity against viral infection.

75. (Currently Amended) The ~~pharmaceutical composition~~ formulation according to claim 72, wherein said antimicrobial agent comprises an antibiotic in sufficient amount to suppress growth of a microbe and said glutathione is provided in sufficient amount to control free radical reactions associated with the microbe.

76. (Currently Amended) The pharmaceutical ~~composition~~ formulation according to claim ~~60~~ 72, wherein said ~~composition~~ formulation is provided in an oral dosage form

77. (Currently Amended) The ~~pharmaceutical composition~~ formulation according to claim 72, wherein said antibiotic agent comprises an aminoglycoside.

78. (Currently Amended) The ~~pharmaceutical composition~~ formulation according to claim 72, ~~wherein said antibiotic agent comprises~~ comprising a quinolone antibiotic.

79. (Currently Amended) The ~~pharmaceutical composition~~ formulation according to claim 72, wherein said formulation is adapted to modify vascular tone in an organism administered said formulation.

80. (New) A pharmaceutical composition, comprising in combination glutathione, or a pharmaceutically acceptable salt or derivative thereof, and at least one of an antiviral or antimicrobial antibiotic agent, said glutathione being present in an effective amount to at least one of: serve as an effective antioxidant agent; supplement endogenous glutathione consumed as a result of administration of the pharmaceutical composition; alter cardiovascular status of a host; alter a redox status of a host; and alter a gene expression within a host, and said antiviral or antimicrobial agent being present in an effective amount to treat or prophylax a viral or microbial-associated condition of the host.

81. (New) The pharmaceutical composition according to claim 80, comprising, in unit dosage form, glutathione in an amount of at least 250 mg., a sacrificial antioxidant

to preserve the glutathione in a reduced state, an effective amount of a pharmaceutically acceptable topoisomerase inhibitor, and a pharmaceutically acceptable physiologic nitric oxide precursor.

82. (New) The pharmaceutical composition according to claim 80, wherein the antioxidant comprises ascorbic acid.

83. (New) The pharmaceutical composition according to claim 80, further comprising an antibiotic having activity against mycoplasma infection.

84. (New) The pharmaceutical composition according to claim 80, further comprising an antibiotic having activity against viral infection.

85. (New) The pharmaceutical composition according to claim 80, wherein said composition is provided in an oral dosage form.

86. (New) The pharmaceutical composition according to claim 80, comprising an aminoglycoside antibiotic.

87. (New) The pharmaceutical composition according to claim 80, comprising a quinolone antibiotic.